The interaction between platelets and factor VII/VIIa

Transfusion and Apheresis Science

Volumn 28, Issue 3, 2003, Pages 279-283

  Lau, Herbert K F ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Factor VII VIIa; Platelets; Tissue factor

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 9; CELL RECEPTOR; FIBRIN; FIBRINOGEN; PROTEIN ANTIBODY; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN;

BLOOD CLOTTING; BLOOD VESSEL INJURY; CELL INTERACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FIBRIN CLOT; HEMOPHILIA; HEMOSTASIS; HUMAN; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0037410056     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(03)00047-8     Document Type: Review

References (21)

1. Mann K.G. Biochemistry and physiology of blood coagulation. Thromb. Haemost. 82(2):1999;165-174.
2. Morrissey J.H. Tissue factor: an enzyme cofactor and a true receptor. Thromb. Haemost. 86:2001;66-74.
3. Bonn V.J., Bertina R.M. The contributions of Ca, phospholipids and tissue-factor apoprotein to the activation of human blood coagulation factor X by activated factor VII. Biochem. J. 265:1990;327-336.
4. Rao L.V., Rapaport S.I. Factor VIIa catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood. 75:1990;1069-1073.
5. Telgt D.S.C., Macik B.G., McCord D.M., Monroe D.M., Roberts H.R. Mechanisms by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb. Res. 56:1989;603-609.
6. Drake T.A., Morrissey J.H., Edgington T.S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am. J. Pathol. 134:1989;1087-1095.
7. Hoffman M., Monroe D.M., Roberts H.R. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood. 83(1):1994;38-42.
8. Reuning U., Preissner K.T., Muller B.G. Two independent binding sites on monolayers of human endothelial cells are responsible for interaction with coagulation factor VII and factor VIIa. Thromb. Haemost. 69:1993;197-203.
9. Monroe D.M., Hoffman M., Oliver J.A., Roberts H.R. Platelet activity of high-dose factor VIIa is independent of tissue factor. Brit. J. Haematol. 99:1997;542-547.
10. Hedner U., Glazer S., Pingel K., Alberts K.A., Blomback M., Schulman S.et al. Successful use of recombinant factor VIIa in patient with severe hemophilia A during synovectomy. Lancet. ii:1988;1193.
11. Macik B.G., Hohneker J., Roberts H.R., Griffin A.M. Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophiliac patient with a high titer inhibitor. Am. J. Hematol. 32:1989;232-234.
12. Macik B.G., Lindley C.M., Lusher J., Sawyer W.T., Bloom A.L., Harrison J.F.et al. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study. Blood Coag. Fibrinol. 4:1993;521-527.
13. O'Marcaigh A.S., Schmalz B.J., Shaughnessy W.J., Gilchrist G.S. Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with sever hemophilia A and a potent inhibitor. Mayo Clinic Proc. 69:1994;641-644.
14. Schmidt M.L., Gamerman S., Smith H.E., Scott J.P., DiMichele D.M. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. Am. J. Hematol. 47:1994;36-40.
15. Smith O.P., Hann I.M. rVIIa therapy to secure hemostasis during central line insertion in children with high-responding FVIII inhibitors. Brit. J. Haematol. 92:1996;1002-1004.
16. ten Cate H., Bauer K.A., Levi M., Edgington T.S., Sublett R.D., Barzegar S.et al. The activation of factor X and protheombin by recombinant factor VIIa in vivo is mediated by tissue factor. J. Clin. Invest. 92:1993;1207-1212.
17. Zur M., Radcliffe R.D., Obberdick J., Nemerson Y. The dual role of factor VII in blood coagulation. Initiation and inhibition of a proteolytic system by a zymogen. J. Biol. Chem. 257:1982;5623-5631.
18. Bauer K.A., Mannucci P.M., Gringeri A. Factor IXa-factor VIIIa-surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood. 79:1992;2039-2047.
19. Kristensen J., Killander A., Hippe E., Helleberg C., Ellegard J., Holm M.et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis. 26:1996;159-164.
20. Monroe D.M., Hoffman M., Allen G.A., Roberts H.R. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopenia. Sem. Thromb. Hemost. 26:2000;373-377.
21. Kjalke M., Ezban M., Monroe D.M., Hoffman M., Roberts H.R., Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Brit. J. Haematol. 114:2001;114-120.